Navigation Links
Immediate bisphosphonate use with endocrine therapy reduced recurrence and increased survival in postmenopausal early breast cancer
Date:12/7/2011

SAN ANTONIO The addition of zoledronic acid to adjuvant endocrine therapy increased bone mineral density and reduced the risk for disease recurrence among postmenopausal women with early hormone receptor-positive breast cancer, according to new data from the ZO-FAST trial.

Richard de Boer, M.D., of the Royal Melbourne Hospital in Victoria, Australia, presented long-term data from the Zometa-Femara Adjuvant Synergy Trial (ZO-FAST) trial at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium, held Dec. 6-10, 2011.

De Boer and colleagues explored adding zoledronic acid, an intravenous bisphosphonate, to adjuvant endocrine therapy to reduce bone mineral density loss seen with aromatase inhibitors and to improve survival outcomes.

When he presented initial data from ZO-FAST at the 2010 CTRC-AACR San Antonio Breast Cancer Symposium, de Boer indicated that early zoledronic acid resulted in a significantly improved bone mineral density and an improved disease-free survival. At this year's symposium, he reported long-term data and data on the effect of menopausal status at breast cancer diagnosis on disease-free survival.

Researchers randomly assigned 1,065 patients who were about to commence letrozole, an aromatase inhibitor, to receive immediate zoledronic acid every six months or to a delayed group where zoledronic acid was started at a later time only if the patient experienced a fracture or a documented fall in bone mineral density.

After 60 months of follow-up, "the primary endpoint of the trial was successfully achieved up-front zoledronic acid significantly decreased bone mineral density loss in both the lumbar spine and the hip," de Boer said. "The secondary endpoint of an improvement in disease-free survival was also met with a 34 percent decrease in disease recurrence in the patients receiving the up-front zoledronic acid."

Researchers conducted an exploratory subgroup analysis based on menopausal status at the time of breast cancer diagnosis. Data indicated that in women who were truly menopausal at diagnosis, immediate treatment with zoledronic acid reduced the risk for disease recurrence by 29 percent and improved overall survival by 35 percent.

"In addition, patients in the delayed group, who did not start with zoledronic acid but who switched to start at a later time, also appeared to benefit from the zoledronic acid with an improvement in disease outcomes compared with those women who never started the bisphosphonate," de Boer said.

Additional studies are needed to fully define the patient populations most likely to benefit from adjuvant zoledronic acid in this setting.

Until then, "patients with hormone receptor-positive breast cancer who are postmenopausal and about to commence letrozole have the option of considering the addition of zoledronic acid primarily to maintain bone mineral density but also with the aim of reducing the risk for disease recurrence," de Boer said.


'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Canadian Journal of Cardiology publishes report on delayed vs. immediate coronary stenting
2. Immediate use of an IUD following abortion more likely to prevent unintended pregnancies
3. Enlarged prostate: Study demonstrates immediate and long-term benefits of laser treatment
4. Immediate treatment can alleviate future back problems
5. Studies identify complications in women undergoing mastectomy and immediate breast reconstruction
6. Study finds more Americans bypassing their personal physician when immediate treatment required
7. Putting focus on immediate health effects may improve weight loss success
8. Universal HIV testing and immediate treatment could reduce but not eliminate HIV/AIDS epidemic
9. Make An Immediate Difference On Earth Day - AquaBella Organic Solutions Will Help - As A Gift
10. doeLegal Delivers Real-Time Analytics for Immediate Electronic Billing Control
11. Mega Stock Picks (megastockpicks.com) Initiates Coverage on FDA Approval for POZEN, Inc.(NasdaqGM: POZN) Drug Vimovo with Immediate Buy Recommendation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... Newark, NJ (PRWEB) , ... May 27, 2016 , ... ... been named as YWCA Tribute to Women and Industry (TWIN) 2016 honorees. The ... to their workplace. For this year, Geri Boone, Director of the MLTSS (Managed Long-Term ...
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst nurses ... time to shed lights on the variety of topics detailing why we appreciate nurses ... tackles why this career has gone from being in a major recession to one ...
(Date:5/27/2016)... ... May 27, 2016 , ... This campaign aims to provide a path to ... society can control and change. , As nearly 795,000 Americans suffering from a new ... United States. Plus, with an estimated 129,000 of these people dying from stroke, it’s ...
(Date:5/27/2016)... ... 27, 2016 , ... In response to meager public awareness, ... of the plight of aphasia. In collaboration with the American Aphasia Association, a ... The link between stroke and aphasia is relatively unknown, but through collaboration with ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed at ... inspiring human interest stories, courtesy of leaders in the nursing and health care ... industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones & ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 26, 2016 According to a new ... Market - U.S. Industry Analysis, Size, Share, Growth, Trends, and ... the U.S. was valued at US$ 5.89 Bn in 2014 ... from 2015 to 2023 to reach US$ 7.99 Bn in ... and emerging needle free drug delivery devices and the market ...
(Date:5/26/2016)... 2016 Since its commercial introduction ... essential life science tool for conducting genetic studies in ... reveals in its new report that the industry sits ... powered by a range of new applications in the ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the ...
(Date:5/25/2016)... and GERMANTOWN, Maryland , May 25, ... QGEN ; Frankfurt Prime Standard: QIA) today announced that the ... Therawis Diagnostics GmbH to develop and commercialize predictive assays in ... PITX2 as a marker to predict effectiveness of anthracycline treatment ... "We are pleased to partner with Therawis, which developed ...
Breaking Medicine Technology: